These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 18408485

  • 21. Gadolinium and nephrogenic systemic fibrosis: association or causation.
    Kurtkoti J, Snow T, Hiremagalur B.
    Nephrology (Carlton); 2008 Jun; 13(3):235-41. PubMed ID: 18221255
    [Abstract] [Full Text] [Related]

  • 22. Nephrogenic systemic fibrosis: a clinicopathologic study of six cases.
    Pryor JG, Poggioli G, Galaria N, Gust A, Robison J, Samie F, Hanjani NM, Scott GA.
    J Am Acad Dermatol; 2007 Jul; 57(1):105-11. PubMed ID: 17412451
    [Abstract] [Full Text] [Related]

  • 23. Nephrogenic systemic fibrosis: history and epidemiology.
    Thomsen HS.
    Radiol Clin North Am; 2009 Sep; 47(5):827-31, vi. PubMed ID: 19744597
    [Abstract] [Full Text] [Related]

  • 24. Gadolinium use in patients with kidney disease: a cause for concern.
    Perazella MA, Rodby RA.
    Semin Dial; 2007 Sep; 20(3):179-85. PubMed ID: 17555477
    [Abstract] [Full Text] [Related]

  • 25. [Nephrogenic systemic fibrosis possibly caused by gadolinium-containing contrast agent].
    van der Meij N, Keur I, van Lienden KP, Scheepstra CG, Bos JD.
    Ned Tijdschr Geneeskd; 2007 Dec 29; 151(52):2898-903. PubMed ID: 18257437
    [Abstract] [Full Text] [Related]

  • 26. [Nephrogenic systemic fibrosis: another problem for patients with chronic renal failure].
    Michelet PR, Chopard CS, Martin PY, Vallée JP.
    Rev Med Suisse; 2008 Mar 05; 4(147):576-8, 580. PubMed ID: 18402015
    [Abstract] [Full Text] [Related]

  • 27. Nephrogenic systemic fibrosis: experimental studies confound prevailing theory of free gadolinium as a causative factor.
    Jakobsen J.
    Acta Radiol; 2008 Jul 05; 49(6):616-7. PubMed ID: 18568551
    [No Abstract] [Full Text] [Related]

  • 28. MRI gadolinium-based contrast agents. Radiologists beware!
    Goullé JP, Cattanéo A, Saussereau E, Mahieu L, Guerbet M, Lacroix C.
    Ann Pharm Fr; 2009 Sep 05; 67(5):335-9. PubMed ID: 19695369
    [Abstract] [Full Text] [Related]

  • 29. Nephrogenic systemic fibrosis and the role of gadolinium contrast media.
    van der Molen AJ.
    J Med Imaging Radiat Oncol; 2008 Aug 05; 52(4):339-50. PubMed ID: 18811757
    [Abstract] [Full Text] [Related]

  • 30. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.
    Canavese C, Mereu MC, Aime S, Lazzarich E, Fenoglio R, Quaglia M, Stratta P.
    J Nephrol; 2008 Aug 05; 21(3):324-36. PubMed ID: 18587720
    [Abstract] [Full Text] [Related]

  • 31. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis.
    Peak AS, Sheller A.
    Ann Pharmacother; 2007 Sep 05; 41(9):1481-5. PubMed ID: 17684032
    [Abstract] [Full Text] [Related]

  • 32. A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger?
    Singh M, Davenport A, Clatworthy I, Lewin J, Deroide F, Hubbard V, Rustin MH.
    Br J Dermatol; 2008 Jun 05; 158(6):1358-62. PubMed ID: 18363754
    [Abstract] [Full Text] [Related]

  • 33. Nephrogenic systemic fibrosis: an overview.
    Cowper SE.
    J Am Coll Radiol; 2008 Jan 05; 5(1):23-8. PubMed ID: 18180005
    [Abstract] [Full Text] [Related]

  • 34. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?
    Thomsen HS, Morcos SK, Dawson P.
    Clin Radiol; 2006 Nov 05; 61(11):905-6. PubMed ID: 17018301
    [No Abstract] [Full Text] [Related]

  • 35. Nephrogenic systemic fibrosis: more questions and some answers.
    Morcos SK, Thomsen HS.
    Nephron Clin Pract; 2008 Nov 05; 110(1):c24-31; discussion c32. PubMed ID: 18688172
    [Abstract] [Full Text] [Related]

  • 36. [Nephrogenic systemic fibrosis and use of MR contrast media].
    Christiansen RE, Sviland L, Sekse I, Svarstad E.
    Tidsskr Nor Laegeforen; 2009 Jan 29; 129(3):180-2. PubMed ID: 19180161
    [Abstract] [Full Text] [Related]

  • 37. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis.
    Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P.
    Br J Dermatol; 2008 Feb 29; 158(2):273-80. PubMed ID: 18067485
    [Abstract] [Full Text] [Related]

  • 38. Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency.
    Chewning RH, Murphy KJ.
    J Vasc Interv Radiol; 2007 Mar 29; 18(3):331-3. PubMed ID: 17377176
    [Abstract] [Full Text] [Related]

  • 39. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States.
    Thomsen HS.
    Radiol Clin North Am; 2009 Sep 29; 47(5):871-5, vii. PubMed ID: 19744601
    [Abstract] [Full Text] [Related]

  • 40. Nephrogenic systemic fibrosis: center case review.
    Lauenstein TC, Salman K, Morreira R, Tata S, Tudorascu D, Baramidze G, Singh-Parker S, Martin DR.
    J Magn Reson Imaging; 2007 Nov 29; 26(5):1198-203. PubMed ID: 17969162
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.